Med 11 AG
MED-11 AG has contracted with Symbio LLC, a Clinical Trial Management Services Company to develop the ‘clinical trial protocol’ for Med-11’s Lung Cancer Test
Med 11 AG / Contract Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- MED-11 AG has contracted with Symbio LLC, a Clinical Trial Management Services Company (www.symbioresearch.com) to develop the ‘clinical trial protocol’ for Med-11’s Lung Cancer Test. Med-11 has contracted with the Emergo Group (www.emergogroup.com) to prepare and file the Lung Cancer Test ‘exemption application’ as requested by the FDA. This should be completed by March 2008. ZUG, Switzerland -- MED-11 AG, Zug, Switzerland, (Frankfurt Stock Exchange: WKN: A0LGDQ) the holder of two US patented cancer screening test kits for various cancerous and precancerous conditions, has been notified by the USA Food and Drug Administration (FDA) that they may file a 'Investigative Device Exemption' (IDE) application for Med-11’s patented Lung Screen Plus, Breast Screen Plus, and Colon Screen Plus Cancer Screening Tests. If the application is successful, this will reduce the time and cost to commercialize the Cancer Screening Tests in the US. There are no cost-effective, non-invasive screening tests for colon, lung or breast cancer in the US; and cancer is a leading cause of death. Early assessment and prevention can eliminate a large percentage of these deaths; consequently there is an urgent need and vast market potential for these patented products. The FDA informed Med-11 that there are no other non-invasive screening tests for Lung Cancer. Market research indicates that the annual sales of the Cancer Screening Tests for Colon, Breast and Lung Cancers, in the US alone, once approved by the FDA, should exceed $1.5 Billion a year. About MED-11: www.med-11diagnostic.com, www.med-11.ch MED-11 AG is medical service company with a wide range of patented medical products in different market segments. These include patented Cancer Screening Tests, patented Cancer Preventive Dietary Supplements; patent pending Personal Care Products; and prepackaged Modular Medical Clinics. The Company identified ‘medical diagnostics’ and ‘preventive health care’ as sectors of the medical service industry that were experiencing strong growth. As a result of management’s background and experience in the United States pharmaceutical, nutraceutical and retail industry, Med-11 made several investments and acquired the United States and Japanese Patents to, Screening Tests for Colon Cancer, Lung Cancer and Breast Cancer; the worldwide Licenses to manufacture and distribute certain Cancer Preventive Dietary Supplements; the worldwide Licenses to manufacture and distribute Modular Medical Clinics; and distribution agreements for various Personal Care Nutraceutical Products. Through the provision, by Medical Practioners, of evidence-based clinical proof of each products safety and efficacy, the Company aims to acquire a major position in this expanding market. In January, 2007 MED-11 entered into a medical partnership agreement with Med-MD, LLC (the 'Physician Partnership') to distribute Med-11’s products through licensed physicians, medical specialists, registered nurses and medical practioners, throughout the United States. In October, 2007, Med-11 concluded an exclusive worldwide license with Braun Megazebo Structures, to manufacture and distribute Modular Medical Clinics. These prepackaged, self contained Medical Clinics, including operating theaters and nursing stations, are designed to be erected in any location. They can be used as day surgery clinics, medical screening facilities and in medical relief operations. For further information contact: Karsten Behrens, Investor Relations: Phone: +41-41-560-8553 or Email: Behrens@med-11.com or Mail to: MED-11 AG, Alpenstrasse 7, CH-6300, Zug, Switzerland. 16.01.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden